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Abstract
Background: Biomarkers that can be used to accurately assess the residual risk of disease recurrence in women
with hormone receptor–positive breast cancer are clinically valuable. We evaluated the prognostic value of the
Breast Cancer Index (BCI), a continuous risk index based on a combination of HOXB13:IL17BR and molecular grade
index, in women with early breast cancer treated with either tamoxifen alone or tamoxifen plus octreotide in the
NCIC MA.14 phase III clinical trial (ClinicalTrials.gov Identifier NCT00002864; registered 1 November 1999).
Methods: Gene expression analysis of BCI by real-time polymerase chain reaction was performed blinded to
outcome on RNA extracted from archived formalin-fixed, paraffin-embedded tumor samples of 299 patients with
both lymph node–negative (LN−) and lymph node–positive (LN+) disease enrolled in the MA.14 trial. Our primary
objective was to determine the prognostic performance of BCI based on relapse-free survival (RFS). MA.14 patients
experienced similar RFS on both treatment arms. Association of gene expression data with RFS was evaluated in
univariate analysis with a stratified log-rank test statistic, depicted with a Kaplan-Meier plot and an adjusted Cox
survivor plot. In the multivariate assessment, we used stratified Cox regression. The prognostic performance of an
emerging, optimized linear BCI model was also assessed in a post hoc analysis.
Results: Of 299 samples, 292 were assessed successfully for BCI for 146 patients accrued in each MA.14 treatment
arm. BCI risk groups had a significant univariate association with RFS (stratified log-rank p = 0.005, unstratified log-
rank p = 0.007). Adjusted 10-year RFS in BCI low-, intermediate-, and high-risk groups was 87.5 %, 83.9 %, and
74.7 %, respectively. BCI had a significant prognostic effect [hazard ratio (HR) 2.34, 95 % confidence interval (CI)
1.33–4.11; p = 0.004], although not a predictive effect, on RFS in stratified multivariate analysis, adjusted for
pathological tumor stage (HR 2.22, 95 % CI 1.22–4.07; p = 0.01). In the post hoc multivariate analysis, higher linear
BCI was associated with shorter RFS (p = 0.002).
Conclusions: BCI had a strong prognostic effect on RFS in patients with early-stage breast cancer treated with
tamoxifen alone or with tamoxifen and octreotide. BCI was prognostic in both LN− and LN+ patients. This
retrospective study is an independent validation of the prognostic performance of BCI in a prospective trial.
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Background
The majority of invasive breast cancers express the
estrogen receptor (ER) and/or progesterone receptor
(PR), predicting a greater likelihood of response to
hormone therapy. However, 25–30 % of early ER+
and/or PR+ breast cancers relapse despite therapy [1].
Classic clinicopathological parameters do not reveal
the wide molecular heterogeneity between breast tu-
mors and fail to accurately delineate clinical outcome
[2]. Over the past 10 years, gene expression profiling
has emerged as a successful clinical strategy to meet
the need for better methods to assess the risk of re-
currence and to better inform treatment decisions in
patients with hormone receptor–positive (HR+) breast
cancer [3–12].
The Breast Cancer Index (BCI) is a continuous risk
index model of two previously described biomarkers:
molecular grade index (MGI) and HOXB13:IL17BR (H:I)
ratio [5, 12, 13]. The MGI is a five-gene predictor that
recapitulates tumor grade and/or proliferation and is
highly prognostic in patients with ER+ breast cancer [5].
H:I, which was developed independent of tumor grade
and/or proliferation, is prognostic for early and late dis-
tant recurrences and is predictive of adjuvant and ex-
tended adjuvant hormonal benefit in patients with early-
stage HR+, LN− breast cancer [6, 12, 14] who have re-
ceived no adjuvant chemotherapy. MGI together with
H:I provides more accurate prognosis than either bio-
marker alone [5]. BCI has been shown to significantly
delineate 0- to 10- year risk of recurrence beyond stand-
ard clinicopathological factors [9, 12, 13].
The investigators in the NCIC Clinical Trials Group
(CTG) MA.14 clinical trial (ClinicalTrials.gov Identifier:
NCT00002864) randomized women, regardless of lymph
node (LN) status, to tamoxifen (TAM) with or without
octreotide LAR [15]. Our aim in this study was to assess
the prognostic and predictive value of BCI in women
with LN− or LN+ breast cancer who were administered
TAM and were enrolled in NCIC CTG MA.14.
Methods
Study design
The NCIC CTG MA.14 researchers enrolled 667 post-
menopausal women between 1996 and 2000 [15]. Pa-
tients were randomly assigned to arm 1 (TAM 20 mg
orally once daily for 5 years) or arm 2 [TAM 20 mg or-
ally once daily for 5 years plus octreotide long-acting re-
lease (OCT) 90 mg intramuscularly monthly for 5 years
(TAM-OCT)]. Patients were stratified by adjuvant
chemotherapy (none, concurrent, or sequential), LN sta-
tus (none, one to three, four or more, or unknown), and
receptor status (ER+ and/or PR+, ER− and PR−, or ER
and PR unknown). This study was approved by the hu-
man research committees of the Massachusetts General
Hospital, Queen’s University, and McGill University. All
patients provided written informed consent before trial
participation. In July 2000, the duration of OCT was
reduced from 5 to 2 years because of a greater inci-
dence of gallbladder toxicity in the OCT arm of
National Surgical Adjuvant Breast and Bowel Project
B-29. The conduct of the study was overseen by an
NCIC CTG study team; Novartis Canada, which pro-
vided the OCT; and the independent NCIC CTG Data
and Safety Monitoring Committee.
Study population
Patients had histologically proven adenocarcinoma of
the breast with satisfactory surgical removal of the
tumor by lumpectomy or total mastectomy [15]. Patients
were to have no previous or concurrent malignancies ex-
cept adequately treated carcinoma of the skin (basal
cell), cervix, endometrium, colon, or thyroid treated
more than 5 years before study entry, and they had to
have a life expectancy of at least 5 years. Tumors could
be ER+ and/or PR+ (biochemical value ≥10 fmol/mg or
positive by immunohistochemistry), negative, or un-
known. Baseline serum was assessed for insulin-like
growth factor 1, insulin-like growth factor-binding pro-
tein 3, and C-peptide for 646 patients (96.9 %), and 25-
hydroxy vitamin D was centrally assessed for 607 of the
MA.14 patients (91 %) [15, 16].
Study endpoints
The primary endpoint of the MA.14 trial was event-
free survival (EFS). Events included recurrence of dis-
ease, second malignancy, or death due to any cause.
Overall survival (OS) was a secondary endpoint.
Relapse-free survival (RFS) was also a secondary end-
point of the MA.14 trial, and it was defined as the
time from randomization to the time of recurrence of
the primary disease alone, including local and ipsilat-
eral nodal recurrence, excluding contralateral breast
cancer, with censoring at longest follow-up or death
due to another cause. RFS is the primary endpoint
for this investigation.
MA.14 trial experience
EFS was the primary endpoint of MA.14. At the final
analysis at a median of 7.9 years, the stratified hazard ra-
tio (HR) for TAM+OCT to TAM was 0.93 [95 % confi-
dence interval (CI) 0.71–1.22; p = 0.62] [15]. OS had an
HR of 0.97 (95 % CI 0.69–1.37; p = 0.86). The RFS HR
was 0.84 (95 % CI, 0.59–1.18; p = 0.31). Patients allo-
cated to octreotide had an absolute 2.7 % lower rate of
recurrence during the study period. At the median 9.8-
year trial follow-up, the RFS HR was 0.87 (95 % CI
0.63–1.21; p = 0.40). The median 9.8-year trial follow-up
was used for these investigations.
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Study objectives
The primary objective of this investigation was to exam-
ine whether BCI has a prognostic association with RFS.
We used pooled data across both MA.14 treatment
arms. Secondary objectives included exploration of
whether the BCI classification (low vs. medium and/or
high) had a predictive effect on RFS.
BCI analytic methods
For each formalin-fixed, paraffin-embedded tumor
sample, three 8-μm tissue sections were subjected to
gross macrodissection to enrich for tumor content.
RNA extraction, amplification, and real-time time
quantitative polymerase chain reaction (RT-qPCR) were
performed at bioTheranostics Inc. (San Diego, CA, USA),
a Clinical Laboratory Improvements Amendments–
certified laboratory, with researchers blinded to clinical
outcome [5, 6, 17]. The prespecified BCI genes, primer
and probe sequences, RT-qPCR, and calculation of H:I
and MGI were performed as previously described [5, 6].
Patient samples were excluded if there was insufficient
RNA. The average cycle threshold for normalizing genes
was >28.5. A continuous risk model called BCI was
previously built by combining H:I and MGI. BCI was
categorized into three levels: low-risk BCI <5, inter-
mediate risk 5 ≤ BCI < 6.4, and high-risk BCI ≥6.4 [13].
These prespecified BCI cutoffs were chosen on the
basis of previously established and validated cutoffs for
LN−, HR+ patients with breast cancer who did not re-
ceive adjuvant chemotherapy [5, 13]. During this study,
a second, “optimized” linear model of BCI (linear BCI)
was developed and a post hoc analysis of the prognos-
tic performance of linear BCI was performed using the
specified risk groups as described previously [9, 12].
Table 1 Baseline patient and tumor characteristics
Tamoxifen-treated (n = 146) Tamoxifen + octreotide–treated (n = 146) Total (n = 292)
Number % Number % Number %
Age, yr
<60 71 49 65 45 136 47
≥60 75 51 81 55 156 53
Race
Caucasian 142 97 137 94 279 96
Non-Caucasian 4 3 9 6 13 4
Performance status
0, unknown 106 73 118 81 224 77
1, 2 40 27 28 19 68 23
Tumor pathologic classification
0, 1, in situ 87 60 91 62 178 61
2, 3A, 4, unknown 59 40 55 38 114 39
Node pathology classification
0 74 51 75 51 149 51
1, 2, unknown 72 49 71 49 143 49
Breast surgery type
Total mastectomy 50 34 58 40 108 37
Other, segmental mastectomy 96 66 88 60 184 63
Number of positive axillary nodes (R)
0 75 51 74 51 149 51
1–3, 4+, unknown 71 49 72 49 143 49
Estrogen/progesterone receptor status (R)
Negative, unknown 14 10 10 7 24 8
Positive 132 90 136 93 268 92
Adjuvant chemotherapy (R)
None 96 66 94 64 190 65
Concurrent, sequential 50 34 52 36 102 35
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Statistical analyses
We used Fisher’s exact test to examine whether there
were significant imbalances by treatment arm and strati-
fication factors in who was or was not assessable for
BCI. A histogram of continuous gene expressions for
BCI, H:I, and MGI was created to examine whether a
Box-Cox transformation should be considered to reduce
asymmetry and stabilize variances. In univariate testing,
we used a stratified log-rank test statistic. Graphical de-
piction was created with an unadjusted Kaplan-Meier
plot and adjusted Cox survivor plot, where adjustment
was by MA.14 trial treatment, stratification factors, and
other factors with significant multivariate associations
with RFS. Exploratory, stratified, stepwise forward Cox
regressions were performed, whereby baseline patient and
tumor characteristics were added if two-sided p ≤ 0.05
with a likelihood ratio criterion test statistic has approxi-
mately a chi-square distribution with 1 degree of freedom.
The Cox assumption of proportional hazards was exam-
ined with plots of log-cumulative hazards versus follow-
up time. Factors with significant time-to-event RFS associ-
ations and subgroups with crossing of cumulative hazards
plots would have been considered to have substantive
nonproportionality. An adjusted Cox model was used to
estimate adjusted 5- and 10-year RFS [18, 19].
Results
Of the 667 MA.14 patients, 299 patients had banked
tumor blocks. The patients with banked tumor blocks
were not significantly different from those without, when
classified by treatment arm and stratification factors; by
LN status (p = 0.90); hormone receptor status (p = 0.19);
or adjuvant chemotherapy (p = 0.90). The patients had
similar median follow-up by trial arm of 10.01 years on
TAM and 10.12 years on TAM-OCT, compared with the
median follow-up of 9.8 years in the full trial. The pa-
tient group of LN−, HR+ patients who did not receive
adjuvant chemotherapy, the type of patients from whom
BCI was initially developed, was similar across treatment
arms, with 63 patients on TAM and 58 patients on
TAM-OCT.
From the 299 patients with blocks, 292 samples passed
internal analytical quality control (REporting recom-
mendations for tumor MARKer prognostic studies
[REMARK] diagram in Additional file 1: Figure S1).
The RT-qPCR histograms for BCI (Additional file 2:
Figure S2a), H:I (Additional file 2: Figure S2b), and
MGI (Additional file 2: Figure S2c) indicated reason-
ably symmetrical distributions. Baseline patient char-
acteristics are provided in Table 1. Each trial arm had
146 patients assessed, and the patients were similar
by trial arm. Of note, 51 % of the investigative group
were LN−, 92 % were HR+, and 35 % received adju-
vant chemotherapy.
BCI risk groups had a significant univariate association
with RFS (stratified log-rank p = 0.005; unstratified log-
rank p = 0.007) (Fig. 1), with the expected direction that
low BCI had the highest RFS, medium BCI had inter-
mediate RFS, and high BCI had lowest RFS. In stratified
multivariate analysis, larger pathologic tumor stage (HR
2.22, 95 % CI 1.22–4.07; p = 0.01), and higher continuous
BCI (HR 2.34, 95 % CI 1.33–4.11; p = 0.004) were associ-
ated with worse RFS (Table 2). The interaction of BCI
and trial treatment was not significant (p = 0.28). The in-
teractions of treatment with LN status (p = 0.88) and
with adjuvant chemotherapy (p = 0.81) also were not sig-
nificant. There was no evidence of substantive nonpro-
portional hazards.
Stratified log rank p-value = 0.005
Fig. 1 Risk-free survival Kaplan-Meier plot of Breast Cancer Index (BCI). CTG Clinical Trials Group
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The adjusted Cox survivor plot (Fig. 2) depicts cat-
egorical BCI experience (p = 0.007) adjusted for the
effects of treatment, stratification factors (ER and PR
status, LN status, and adjuvant chemotherapy), and
pathologic tumor stage. The HR of intermediate BCI to
low BCI was 1.28 (95 % CI 0.65–2.52), while that of high
BCI to low BCI was 2.53 (95 % CI 1.36–4.71). The BCI
low-risk group had 5- and 10-year RFS rates of 94 % and
87.5 %, the BCI intermediate-risk group had 5- and
10-year RFS rates of 91.8 % and 83.9 %, and the BCI
high-risk group had 5- and 10-year RFS rates of
81.5 % and 74.7 % (Table 3).
At the time of this study, an emerging optimized linear
model of BCI (linear BCI) was developed and validated
in several independent cohorts [9, 12]. A post hoc ana-
lysis with 116 LN+ patients who had HR+ tumors indi-
cated that higher continuous linear BCI was associated
with shorter RFS (p = 0.002. The results of this univari-
ate analysis are depicted in Additional file 3: Figure S3.
Discussion
We previously showed that BCI predicts risk of recur-
rence in patients with LN−, ER+ breast cancer [9, 12, 13].
In this retrospective analysis of a nested MA.14 study,
BCI had a strong prognostic association with disease
recurrence in postmenopausal patients with LN− and
LN+ breast cancer treated with TAM. The probability
of being disease-free at 10 years was 87.5 % for low
BCI, 83.9 % for intermediate BCI, and 74.7 % for high
BCI. Our findings are consistent with those described
in previous reports [9, 13, 20]. In the Stockholm trial,
the 10-year distant metastasis rates in TAM–treated,
ER+, LN− patients were 1.7 %, 16.9 %, and 20 % for
low, intermediate, and high BCI, respectively [13]. In
another large case–control study, 10-year risk of breast
cancer death among patients with ER+, LN−, breast
cancer treated with TAM were 3.5 % , 7.0 %, and
12.9 % for low, intermediate, and high BCI, respect-
ively [20]. The RFS rates for BCI in our study are
lower than in previous trials [9, 13]; however, they
are adjusted for the effects of potential confounders
between studies (trial treatment, LN status, adjuvant
chemotherapy, and hormone receptor status). As BCI
was developed in ER+ patients, the inclusion of a
substantial (8 %) number of ER−/ER unknown patients
in the present study likely impacted the prognostic per-
formance of BCI. Furthermore, this difference in per-
formance is likely attributable to the inclusion of the
higher-risk LN+ patients in the present study cohort as
compared with previous cohorts.
Patients with axillary node metastases are traditionally
considered as having a poor prognosis [1]. Interestingly,
half of the patients in our trial were classified as low
risk, again confirming that even among LN+ patients
there is a subgroup of patients with a good prognosis
[21–24]. Because most patients with LN+ breast cancer





Pathologic T status T2 or higher vs. lower
than T2
2.22 (1.22–4.07) 0.01
Continuous cubic BCI 2.34 (1.33–4.11) 0.004
T tumor, BCI Breast Cancer Index, CI confidence interval
ap Value is based on the likelihood ratio criterion likelihood ratio criterion test
statistic has approximately a chi-square distribution with 1 degree of freedom.
Stratified log rank p-value = 0.007
Fig. 2 Risk-free survival adjusted Cox survivor plot by Breast Cancer Index (BCI), adjustments by treatment, MA.14 stratification factors, and
pathologic tumor stage. CTG Clinical Trials Group
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in our study received adjuvant chemotherapy or hor-
mone therapy, we could not evaluate the prognostic
value of BCI in patients with untreated LN+ disease.
A recent subgroup analysis of the LN+ MA.14 pa-
tients revealed that BCI was a significant prognostic
factor for HR+ patients who were treated with TAM
[25]. These findings could have important implica-
tions for treatment decisions because not all patients
with LN+ breast cancer require aggressive treatment
[21, 24]. However, validation of these findings in add-
itional cohorts of patients with LN+ breast cancer is
warranted.
At the time of this study, an emerging optimized linear
model of BCI (linear BCI) was developed and validated
in several independent cohorts [9, 13]. Our post hoc
analysis of linear BCI in the MA.14 cohort revealed
that linear BCI had prognostic results similar to those
reported in other cohorts [9, 12]. The MA.14 trial
precluded robust comparisons with the unoptimized
BCI.
Our study has limitations. With the two trial arms
having similar RFS experience, it would have been more
difficult to see a predictive effect for BCI. All MA.14 pa-
tients were postmenopausal, so our results are not
generalizable to premenopausal women. Around one-
third of women in our trial received adjuvant chemo-
therapy in addition to TAM, and the multivariate ana-
lysis was stratified by receipt of chemotherapy; however,
the number of patients in the chemotherapy subgroup is
too small to infer what effect, if any, chemotherapy had
on disease outcomes. As well, the number of patients
available for analysis in our study was relatively small
and did not allow us to accurately quantify the differ-
ences among LN− and LN+ patients or, more specif-
ically, the experience in our original target population
(ER+, LN−, no chemotherapy subgroup) because the
latter group of patients had only 11 RFS events,
which is too few to allow further subdivision by BCI
risk group classification. Our exploratory analysis
showed that BCI continued to have a significant prog-
nostic effect in TAM-treated patients after stratifica-
tion or adjustment by standard factors, including LN
status and tumor size. Our retrospective analysis
included only a subset of patients from the MA.14
trial, although we found that those assessed for BCI
were similar to those who were not. Thus, the prog-
nostic and predictive effects of BCI might differ be-
cause of the inclusion of disease-free survival events
such as locoregional breast recurrences. Further re-
search is needed to show if these results can be ex-
tended to other populations of breast cancer patients,
particularly younger women.
In summary, for TAM-treated patients, BCI has been
shown to have a prognostic but not predictive effect on
RFS that extends beyond traditional breast cancer pa-
rameters such as LN status, tumor size, and treatment.
The results of this study affirm those published recently
by our group and others and will contribute to the as-
sessment of the clinical utility of BCI evaluation in guid-
ing adjuvant therapy choices for patients.
Conclusions
BCI had a strong prognostic effect on RFS in patients
with early-stage breast cancer treated with tamoxifen
alone or with tamoxifen and octreotide. BCI was prog-
nostic in both LN− and LN+ patients. This retrospective
study is an independent validation of the prognostic per-
formance of BCI in a prospective trial.
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